01.03.24
Qualia Senolytic, a branded supplement marketed by NeuroHacker Collective formulated with nine ingredients designed to help the body eliminate senescent cells, appears to be beneficial in improving joint health and performance.
In a double-blind, placebo-controlled human clinical trial involving 36 men and women between the ages of 35 and 79, those who took the dietary supplement saw a 68% reduction in self-reported joint discomfort scores, and a 66% improvement in joint performance scores, based on multiple questionnaires, over a period of six months. While there was also a positive placebo response, Qualia Senolytic significantly outperformed the placebo group.
Qualia Senolytic contains several botanical extracts, including Fisetin,Indena’s Quercefit Quercetin, Verdure Sciences’ Longvida Optimized Curcumin, olive leaf extract, soybean seed extract, luteolin, milk thistle fruit extract, piperlongumine, and a Panax notoginseng and Rosa rugosa extract marketed by NuLiv Science as Senactiv.
The treatment group took six capsules daily for two consecutive days, followed by a 12-day washout period, which was done three times over about a one-month period.
“These studies are very expensive to conduct,” said Daniel Schmachtenberger, director of R&D and co-founder of the Neurohacker Collective, which developed Qualia Senolytic. “But people deserve to know the supplements they take actually work. Very few supplement companies seem willing to subject their product claims to the highest standard of scientific evidence. Our science team at Qualia is the exact opposite. We were thrilled to subject Qualia Senolytic to rigorous clinical testing standards because we were confident these results would occur. Now that they have, we’re hoping even more people will discover how transformative Qualia Senolytic can be to their aging process.”
The questionnaires used in the study were part of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), which evaluates pain, stiffness, and functional limitation.
Cellular senescence, in which cells permanently cease to divide without undergoing cell death, leads to the progressive accumulation of senescent cells in the body over time as part of the aging process. It’s thought that purging senescent cells from the body may result in anti-aging benefits. Cells that joints rely on for structure and function, such as fibroblasts, endothelial cells, tissue-resident macrophages, and chondrocytes, are among the most susceptible to cellular senescence, the company reports.
In a double-blind, placebo-controlled human clinical trial involving 36 men and women between the ages of 35 and 79, those who took the dietary supplement saw a 68% reduction in self-reported joint discomfort scores, and a 66% improvement in joint performance scores, based on multiple questionnaires, over a period of six months. While there was also a positive placebo response, Qualia Senolytic significantly outperformed the placebo group.
Qualia Senolytic contains several botanical extracts, including Fisetin,Indena’s Quercefit Quercetin, Verdure Sciences’ Longvida Optimized Curcumin, olive leaf extract, soybean seed extract, luteolin, milk thistle fruit extract, piperlongumine, and a Panax notoginseng and Rosa rugosa extract marketed by NuLiv Science as Senactiv.
The treatment group took six capsules daily for two consecutive days, followed by a 12-day washout period, which was done three times over about a one-month period.
“These studies are very expensive to conduct,” said Daniel Schmachtenberger, director of R&D and co-founder of the Neurohacker Collective, which developed Qualia Senolytic. “But people deserve to know the supplements they take actually work. Very few supplement companies seem willing to subject their product claims to the highest standard of scientific evidence. Our science team at Qualia is the exact opposite. We were thrilled to subject Qualia Senolytic to rigorous clinical testing standards because we were confident these results would occur. Now that they have, we’re hoping even more people will discover how transformative Qualia Senolytic can be to their aging process.”
The questionnaires used in the study were part of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), which evaluates pain, stiffness, and functional limitation.
Cellular senescence, in which cells permanently cease to divide without undergoing cell death, leads to the progressive accumulation of senescent cells in the body over time as part of the aging process. It’s thought that purging senescent cells from the body may result in anti-aging benefits. Cells that joints rely on for structure and function, such as fibroblasts, endothelial cells, tissue-resident macrophages, and chondrocytes, are among the most susceptible to cellular senescence, the company reports.
